PASADENA, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, supplies newly manufactured
PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2
for intravenous applications.
According to a Company spokesperson, should the pre-clinical trials for
intravenous use be successful, the Company would likely move toward a
development agreement with the potential of licensing PHER-O2 as part of a new
procedure. The procedure, which remains unnamed to protect the respective
company's proprietary material, could revolutionize a medical procedure that is
used every day through out the world.
Dr. Thomas C. Drees, Ph.D. - President and CEO - commented, "Management has
identified numerous applications for PHER-O2. Our most recent work as an ex-vivo
510(K) device for the transportation of transplant material is going well,
however we are keen to move into intravenous work, which has widespread
application. We feel this effort can move us swiftly toward this goal."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)medancy@allwest.net
Copyright Business Wire 2008
invest at your own risk, based on your own due diligence, at your own risk tolerance
AI
